Skip to content

PSORIASIS Update: Highlights of news and new research

PSORIASIS Update: Highlights of news and new research 1

PSORIASIS Update: Highlights of news and new research. Issue Number: Volume 17 – Issue 1 – January 2009. Author: By Ellen Meyer, Senior Editor. ‘If patients got long-term relief from a new drug, that would boost their self-esteem and allow them to get on with a normal life. And if Amevive gives me long-term relief in the way that cyclosporine did, that would be tremendous news. Malia Obama will study at Harvard after taking a gap year:. Ixekizumab research highlights psoriasis news from the AAD annual meeting. Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his presentation about updates on biosimilars. Recent News.

PSORIASIS Update: Highlights of news and new research 2Study Highlights Psoriasis sufferers may have an increased risk for abdominal aortic aneurysms. April 14, 2016 Categories: Heart News. DALLAS, April 14, 2016 Psoriasis sufferers may face a higher risk of developing abdominal aortic aneurysms, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal. For the updates and new science from the Arteriosclerosis, Thrombosis and Vascular Biology journal follow atvbahajournals. FDA News Release. FDA approves new psoriasis drug Cosentyx. Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. Medical news and health news headlines posted throughout the day, every day.

New Target for Psoriasis Treatment Discovered. The study, published in Science Translational Medicine, highlights for the first time the role of PIM1 and the IL-22 cytokine a protein that sends messages between cells in skin inflammation such as that seen in psoriasis patients. Leading experts discussed advances in research, therapy and patient care for psoriasis and psoriatic arthritis. Christopher Ritchlin from the University of Rochester in New York reviewed updates to the recommendations for psoriatic arthritis treatment, including those from EULAR (European League Against Rheumatism) and GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). Looking for the latest rheumatology news & trends? The new clinician and patient resources compare the latest research on RA and PsA treatments. New PsA resources include a patient summary and clinician summary based on the review Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report. Internet Citation: AHRQ reviews highlight treatment options for rheumatoid and psoriatic arthritis: News and Notes.

Psoriasis Severity Linked To Rising Risk Of Abdominal Aortic Aneurysms

New tailored treatments for psoriasis could become a reality after scientists identified several DNA variants linked to the debilitating skin disease. For the best possible experience using our website we recommend you upgrade to a newer version or another browser. Daily news focus. A number of new treatment options for patients with psoriasis and related conditions have been recently approved or are nearing approval for us by the NHS in England and Scotland. For the best possible experience using our website we recommend you upgrade to a newer version or another browser. Daily news focus. DNA research reveals new hope for psoriasis treatments. For the Treatment of Moderate-to-Severe Plaque Psoriasis INDIANAPOLIS, May 2, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order through a contracted network of specialty pharmacies in the United States. Update on New and Emerging Therapies in the Management of Psoriasis. Highlights of the Skin Disease Education Foundation’s 11th Annual Psoriasis Forum. In part 2 of that phase IIb study, the patients who achieved PASI 75 or better continued in the study, receiving injections every 12 weeks from week 16 through week 52, to determine the longer-term benefits of the various dosages tested. Psoriatic arthritis (PsA) is an autoimmune disorder that often presents serious clinical challenges to practitioners. 10 The last time the organization updated their guidelines was back in 2009,11 and given the influx of new research and approved therapies for PsA, the 2015 update could serve as a useful guidepost (Figure 1, Table 1). The 60+ people who came to the psoriasis research update at SBP on February 2 all had something in common: psoriasis has affected their lives in some way. The event was co-sponsored by SBP and the National Psoriasis Foundation (NPF), and offered patients, patient advocates and even some doctors the opportunity to see and hear how scientists studying autoimmunity are working towards new therapies. Highlights included:. Here, we share Institute and research news, scientist and leadership profiles, industry trends, as well as interviews with interesting people.

New Target For Psoriasis Treatment Discovered

Submit your email address below to receive email alerts about NHLBI related news and highlights from across the Institute. Research has shown psoriasis to be a risk factor for developing atherosclerosis, or hardening of the arteries, which is the major cause of heart attacks. Recent studies indicate that the level or concentration of HDL may not adequately predict heart disease risk. New research offers a glimpse at the infection rates in these vulnerable patients. Ixekizumab research highlights psoriasis news from the AAD annual meeting. VIDEO: Researcher provides update on biosimilars and psoriasis. Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology. Among the highlights are three late-breaking research presentations, including 52-week pooled results from the O ral treatment P soriasis T rials (OPT) Pivotal studies, an integrated safety summary across the OPT development program for oral tofacitinib, and the first presentation of two year results from OPT Extend, the ongoing long-term extension study of tofacitinib in moderate to severe chronic plaque psoriasis. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.